Exploring Potential Epigenetic Biomarkers for Colorectal Cancer Metastasis-Reference-Cited by-同舟云学术

Exploring Potential Epigenetic Biomarkers for Colorectal Cancer Metastasis

Published:2024-01-10 Issue:2 Volume:25 Page:874
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Ajithkumar Priyadarshana¹,Vasantharajan Sai Shyam¹,Pattison Sharon²^ORCID,McCall John L.³^ORCID,Rodger Euan J.¹^ORCID,Chatterjee Aniruddha¹⁴^ORCID

Affiliation:

1. Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand

2. Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand

3. Department of Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin 9016, New Zealand

4. School of Health Sciences and Technology, UPES University, Dehradun 248007, India

Abstract

Metastatic progression is a complex, multistep process and the leading cause of cancer mortality. There is growing evidence that emphasises the significance of epigenetic modification, specifically DNA methylation and histone modifications, in influencing colorectal (CRC) metastasis. Epigenetic modifications influence the expression of genes involved in various cellular processes, including the pathways associated with metastasis. These modifications could contribute to metastatic progression by enhancing oncogenes and silencing tumour suppressor genes. Moreover, specific epigenetic alterations enable cancer cells to acquire invasive and metastatic characteristics by altering cell adhesion, migration, and invasion-related pathways. Exploring the involvement of DNA methylation and histone modification is crucial for identifying biomarkers that impact cancer prediction for metastasis in CRC. This review provides a summary of the potential epigenetic biomarkers associated with metastasis in CRC, particularly DNA methylation and histone modifications, and examines the pathways associated with these biomarkers.

Funder

Royal Society of New Zealand Te Apārangi

Health Research Council of New Zealand

Publisher

MDPI AG

Link

https://www.mdpi.com/1422-0067/25/2/874/pdf

Reference149 articles.

1. Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN;Morgan;Gut,2023

2. Sociodemographic factors and strategies in colorectal cancer screening: A narrative review and practical recommendations;Moons;Acta Clin. Belg.,2020

3. Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies;Keum;Nat. Rev. Gastroenterol. Hepatol.,2019

4. A comparative examination of colorectal cancer burden in European Union, 1990–2019: Estimates from Global Burden of Disease 2019 Study;Sharma;Int. J. Clin. Oncol.,2022

5. Improving outcomes in colorectal cancer: Where do we go from here?;Castells;Eur. J. Cancer,2013

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Coding RNAs and Innate Immune Responses in Cancer;Biomedicines;2024-09-11

2. Moscatilin, a potential therapeutic agent for cancer treatment: insights into molecular mechanisms and clinical prospects;Medical Oncology;2024-08-17

3. Senescence-related signatures predict prognosis and response to immunotherapy in colon cancer;Journal of Gastrointestinal Oncology;2024-06

4. Microsatellite instability: A potential game-changer in colorectal cancer diagnosis and treatment;Results in Chemistry;2024-01